Araceli Biosciences
TIGARD, OR · Biotechnology, Healthcare · 45 employees
Araceli Biosciences is transforming therapeutic discovery with technologies built for speed, precision, and impact. Our advanced High Content Imaging platforms deliver real-time analysis, giving researchers immediate, actionable answers during experiments. Responding at the pace of biology accelerates decision-making, improves candidate selection, and reduces costly downstream failures.
Funding history
- Funding Round — $12.2M — Dec 2025
- Series seed — $11.2M — Apr 2025
- Series seed — $2.5M — Jan 2025
- Series seed — $12.2M — Apr 2023
Recent signals
- May 20, 2026: Launched Araceli Biosciences launched Endeavor® Live Cell, an ultra-high-throughput kinetic imaging solution for drug discovery.
- Apr 16, 2026: Araceli Biosciences Appoints Christine A. Tsingos to Chief Financial Officer
- Dec 09, 2025: Raised $12.2M
- Apr 24, 2025: Raised $11.2M in Series seed
- Jan 15, 2025: Raised $2.5M in Series seed
- May 06, 2024: Araceli Biosciences Appoints Matt Beaudet as President and CEO
- Apr 26, 2023: Raised $12.2M in Series seed
See plans & pricing → Track Araceli Biosciences’s funding, hiring, and signals — with verified contacts — on Fundz.